Patent ID: 8168220

Claim:
A solid dosage form comprising an active-ingredient-containing solid core with a pharmaceutically acceptable carrier and an active ingredient content of about 1 to 20% by weight, based on the total weight of the core, wherein the active ingredient is a hydroxystilbene-containing active ingredient combination consisting essentially of rhaponticin and deoxyrhaponticin, in a ratio by weight of from 10:1 to 1:10, wherein rhaponticin and deoxyrhaponticin, each independently, are in a form selected from a salt, a phenol form, an ester derivative, and an ether derivative, wherein said solid dosage form has a total weight in the range of about 150 mg ±20 mg, a core weight of 84 mg ±10 mg, and an active ingredient content of about 3 to 10 mg per dose unit; wherein said solid dosage for has a uniformity of active ingredient content (averaged over 10 randomly selected individual dose units) not exceeding ±5% by weight based on the total weight of the dose unit; and said solid dosage form is obtained by a method comprising the steps of: a) adding to the total amount of the active ingredient combination the pharmaceutically acceptable carrier in portions and mixing after each addition of the carrier with a ball mill over a period of from 30 minutes to 3 h; and b) consolidating the mixture to give the active ingredient core.